Publications

  1. Kim SP, Shah ND, Karnes RJ, Weight CJ, Shippee ND, Han LC, Boorjian SA, Smaldone MC, Frank I, Gettman MT, Tollefson MK, Thompson RH. Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol. 2013 Jul; 64(1):11-6. Epub 2012 Aug 20. 2269132
    View PubMed
  2. Kovtun IV, Cheville JC, Murphy SJ, Johnson SH, Zarei S, Kosari F, Sukov WR, Karnes RJ, Vasmatzis G. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res. 2013 Jun 1; 73(11):3275-84. Epub 2013 May 21. 2325706
    View PubMed
  3. Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Han LC, Thompson RH, Trinh QD, Sun M, Boorjian SA, Beebe TJ, Tilburt JC. Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. J Urol. 2013 Jun; 189(6):2092-8. Epub 2012 Dec 03. 2289363
    View PubMed
  4. Eisenberg MS, Karnes RJ, Kaushik D, Rangel L, Bergstralh EJ, Boorjian SA. Risk Stratification of Patients with Extraprostatic Extension and Negative Lymph Nodes at Radical Prostatectomy: Identifying Optimal Candidates for Adjuvant Therapy. J Urol. 2013 May 29. [Epub ahead of print] 2327478
    View PubMed
  5. Joniau S, Tosco L, Briganti A, Vanden Broeck T, Gontero P, Karnes RJ, Spahn M, Van Poppel H, for the European Multicenter Prostate Cancer Clinical and Translational research group (EMPaCT). Results of surgery for high-risk prostate cancer. Curr Opin Urol. 2013 May 22. [Epub ahead of print] 2325652
    View PubMed
  6. Tollefson MK, Karnes RJ, Rangel LJ, Bergstralh EJ, Boorjian SA. The impact of clinical stage on prostate cancer survival following radical prostatectomy. J Urol. 2013 May; 189(5):1707-12. Epub 2012 Nov 15. 2284683
    View PubMed
  7. Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R, European Multicenter Prostate Cancer Clinical and Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol. 2013 Apr; 63(4):693-701. Epub 2012 Sep 5. 2316493
    View PubMed
  8. Joniau S, Van der Eeckt K, Briganti A, Gontero P, Van Bruwaene S, Karnes RJ, Spahn M, Van Poppel H. Current role of surgery for high risk prostate cancer. Arch Esp Urol. 2013 Apr; 66(3):259-74. 2326455
  9. Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol. 2013 Apr; 189(4):1308-13. Epub 2012 Oct 30. 2281838
    View PubMed
  10. Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, di Muzio N, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A. Survival Following Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiotherapy in Patients With Prostate Cancer: The Impact of Competing Causes of Mortality and Patient Stratification. Eur Urol. 2013 Mar 13. [Epub ahead of print] 2313243
    View PubMed
  11. Kim SP, Shah ND, Weight CJ, Thompson RH, Wang JK, Karnes RJ, Han LC, Ziegenfuss JY, Frank I, Tollefson MK, Boorjian SA. Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer. BJU Int. 2013 Mar 1. [Epub ahead of print] 2308250
    View PubMed
  12. Kim SP, Boorjian SA, Shah ND, Weight CJ, Tilburt JC, Han LC, Thompson RH, Trinh QD, Sun M, Moriarty JP, Karnes RJ. Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. J Urol. 2013 Feb; 189(2):514-20. Epub 2012 Dec 17. 2296271
    View PubMed
  13. Weight CJ, Kim SP, Jacobson DJ, McGree ME, Boorjian SA, Thompson RH, Leibovich BC, Karnes RJ, St Sauver J. The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol. 2013; 63(6):1021-7. 2320742
  14. Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of 11C-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol. 2013; 189(4):1308-13. 2320606
  15. Siddique HR, Parray A, Tarapore RS, Wang L, Mukhtar H, Karnes RJ, Deng Y, Konety BR, Saleem M. BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling. PLoS ONE. 2013; 8(5):e60664. 2324428
  16. Siddique HR, Parray A, Zhong W, Karnes RJ, Bergstralh EJ, Koochekpour S, Rhim JS, Konety BR, Saleem M. BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer. PLoS One. 2013; 8(1):e52993. Epub 2013 Jan 07. 2300505
    View PubMed
  17. Linder BJ, Frank I, Umbreit EC, Shimko MS, Fernandez N, Rangel LJ, Karnes RJ. Standard and saturation transrectal prostate biopsy techniques are equally accurate among prostate cancer active surveillance candidates. Int J Urol. 2012 Dec 20. [Epub ahead of print] 2292864
    View PubMed
  18. Linder BJ, Boorjian SA, Umbreit EC, Carlson RE, Rangel LJ, Bergstralh EJ, Karnes RJ. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer. Int J Urol. 2012 Dec 20. [Epub ahead of print] 2292869
    View PubMed
  19. Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012 Dec; 110(11):1709-13. Epub 2012 Aug 30. 2268024
    View PubMed
  20. Boorjian SA, Tollefson MK, Thompson RH, Rangel LJ, Bergstralh EJ, Karnes RJ. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. J Urol. 2012 Nov; 188(5):1761-6. Epub 2012 Sep 19. 2272619
    View PubMed
  21. Murphy SJ, Cheville JC, Zarei S, Johnson SH, Sikkink RA, Kosari F, Feldman AL, Eckloff BW, Karnes RJ, Vasmatzis G. Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer. DNA Res. 2012 Oct; 19(5):395-406. Epub 2012 Sep 18. 2271850
    View PubMed
  22. Kim SP, Boorjian SA, Shah ND, Karnes RJ, Weight CJ, Moriarty JP, Tollefson MK, Shippee ND, Frank I. Contemporary trends of in-hospital complications and mortality for radical cystectomy. BJU Int. 2012 Oct; 110(8):1163-8. Epub 2012 Mar 22. 2273657
    View PubMed
  23. Karnes RJ, Fernandez CA, Shuber AP. A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria. Mayo Clin Proc. 2012 Sep; 87(9):835-42. Epub 2012 Aug 09. 2263953
    View PubMed
  24. Weight CJ, Kim SP, Karnes RJ, Bergstralh EJ, Cheville JC, Leibovich BC. A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis. Urology. 2012 Aug; 80(2):484.e17-22. Epub 2012 Apr 13. 2238960
    View PubMed
  25. Kosari F, Cheville JC, Ida CM, Karnes RJ, Leontovich AA, Sebo TJ, Erdogan S, Rodriguez E, Murphy SJ, Vasmatzis G. Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer. Am J Pathol. 2012 Jul; 181(1):34-42. Epub 2012 May 26. 2252651
    View PubMed
  26. Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC. The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc. 2012 Jun; 87(6):540-7. 2250731
    View PubMed
  27. Kim SP, Shah ND, Karnes RJ, Weight CJ, Frank I, Moriarty JP, Han LC, Borah B, Tollefson MK, Boorjian SA. The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol. 2012 Jun; 187(6):2011-7. Epub 2012 Apr 11. 2238844
    View PubMed
  28. Tollefson MK, Boorjian SA, Gettman MT, Rangel LJ, Bergstralh EJ, Karnes RJ. Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy. Urol Oncol. 2012 May 10. [Epub ahead of print] 2244809
    View PubMed
  29. Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, Shariat SF. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol. 2012 May; 61(5):961-71. Epub 2012 Jan 23. 2242299
    View PubMed
  30. Hubanks JM, Umbreit EC, Karnes RJ, Myers RP. Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series. Eur Urol. 2012 May; 61(5):878-84. Epub 2011 Dec 05. 2210867
    View PubMed
  31. Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol. 2012 Apr; 61(4):664-75. Epub 2011 Dec 07. 2211658
    View PubMed
  32. Boorjian SA, Tollefson MK, Rangel LJ, Bergstralh EJ, Karnes RJ. Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):56-62. Epub 2011 Aug 02. 2180624
    View PubMed
  33. Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol. 2012 Mar; 61(3):584-92. Epub 2011 Dec 02. 2228553
    View PubMed
  34. Dimonte G, Bergstralh EJ, Bolander ME, Karnes RJ, Tindall DJ. Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancer. Prostate. 2012 Feb; 72(3):280-90. Epub 2011 May 31. 2225303
    View PubMed
  35. Schubert M, Joniau S, Gontero P, Kneitz S, Scholz CJ, Kneitz B, Briganti A, Karnes RJ, Tombal B, Walz J, Hsu CY, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schroder F, van Cangh P, van Poppel H, Spahn M. The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. Adv Urol. 2012; 2012:612707. Epub 2012 Jan 31. 2235851
    View PubMed
  36. Fernandez CA, Millholland JM, Zwarthoff EC, Feldman AS, Karnes RJ, Shuber AP. A noninvasive multi-analyte diagnostic assay: Combining protein and DNA markers to stratify bladder cancer patients. Open Access Journal of Urology. 2012; 4(1):17-26. 2238434
  37. Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV. Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med. 2012; 2012:303019. Epub 2012 Feb 22. 2207285
    View PubMed
  38. Kim SP, Karnes RJ. An Editorial Response to the USPTF. Prostate cancer screening: The case for patient-centered shared decision-making. Journal of Men's Health. 2012; 9(1):5-8. 2228596
  39. Gleeson FC, Clain JE, Karnes RJ, Rajan E, Topazian MD, Wang KK, Levy MJ. Endoscopic-ultrasound-guided tissue sampling facilitates the detection of local recurrence and extra pelvic metastasis in pelvic urologic malignancy. Diagn Ther Endosc. 2012; 2012:219521. Epub 2012 Jun 19. 2257042
    View PubMed
  40. Inman BA, Frank I, Boorjian SA, Akornor JW, Karnes RJ, Leibovich BC, Blute ML, Bergstralh EJ. Dynamic prediction of metastases after radical prostatectomy for prostate cancer. BJU Int. 2011 Dec; 108(11):1762-8. Epub 2011 May 26. 2166811
    View PubMed
  41. Mitchell CR, Umbreit EC, Rangel LJ, Bergstralh EJ, Karnes RJ. Does body mass index "dilute" the predictive property of prostate-specific antigen for tumor volume at radical prostatectomy? Urology. 2011 Oct; 78(4):868-72. Epub 2011 Aug 16. 2184830
    View PubMed
  42. Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV. Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J. 2011 Sep; 13(3):365-77. Epub 2011 May 11. 2163889
    View PubMed
  43. Siddique HR, Mishra SK, Karnes RJ, Saleem M. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res. 2011 Aug 15; 17(16):5379-91. Epub 2011 Jun 28. 2182850
    View PubMed
  44. Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'Oglio M, Srougi M, Scardino PT, Eastham JA. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011 Aug; 60(2):205-10. Epub 2011 Mar 21. 2176557
    View PubMed
  45. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011 Jul 1; 117(13):2883-91. Epub 2011 Jan 10. 2172211
    View PubMed
  46. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011 Jun; 59(6):893-9. Epub 2011 Feb 22. 2151671
    View PubMed
  47. Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol. 2011 May; 59(5):832-40. Epub 2011 Feb 22. 2204845
    View PubMed
  48. Tollefson MK, Gettman MT, Blute ML, Bergstralh EJ, Rangel LJ, Karnes RJ. Serum calcium is not predictive of aggressive prostate cancer after radical prostatectomy. Urology. 2011 May; 77(5):1161-5. Epub 2010 Dec 03. 2129817
    View PubMed
  49. Tollefson MK, Gettman MT, Karnes RJ, Frank I. Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy. J Urol. 2011 May; 185(5):1686-90. Epub 2011 Mar 21. 2155599
    View PubMed
  50. Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA, Tang H, Munz JM, Kosari F, Vasmatzis G. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res. 2010 Nov 15; 70(22):8994-9002. Epub 2010 Nov 09. 2124004
    View PubMed
  51. Tollefson MK, Blute ML, Rangel LJ, Karnes RJ, Frank I. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy. J Urol. 2010 Sep; 184(3):925-9. 2106676
    View PubMed
  52. Karnes RJ, Breau RH, Lightner DJ. Surgery for urethral cancer. Urol Clin North Am. 2010 Aug; 37(3):445-57. 2109296
    View PubMed
  53. Breau RH, Karnes RJ, Jacobson DJ, McGree ME, Jacobsen SJ, Nehra A, Lieber MM, St Sauver JL. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol. 2010 Aug; 184(2):494-9. Epub 2010 Jun 17. 2160182
    View PubMed
  54. Tollefson MK, Blute ML, Rangel LJ, Bergstralh EJ, Boorjian SA, Karnes RJ. The effect of Gleason score on the predictive value of prostate-specific antigen doubling time. BJU Int. 2010 May; 105(10):1381-5. Epub 2009 Oct 26. 1970125
    View PubMed
  55. Boorjian SA, Karnes RJ, Crispen PL, Carlson RE, Rangel LJ, Bergstralh EJ, Blute ML. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol. 2010 Mar; 183(3):1003-9. Epub 2010 Jan 21. 1988026
    View PubMed
  56. Donkena KV, Karnes RJ, Young CY. Vitamins and prostate cancer risk. Molecules. 2010 Mar; 15(3):1762-83. Epub 2010 Mar 12. 1992814
    View PubMed
  57. Umbreit EC, Dozois EJ, Crispen PL, Tollefson MK, Karnes RJ, Blute ML. Radical prostatectomy for prostate cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life. J Am Coll Surg. 2010 Feb; 210(2):232-9. Epub 2009 Dec 03. 1985143
    View PubMed
  58. Karnes RJ, Hatano T, Blute ML, Myers RP. Radical prostatectomy for high-risk prostate cancer. Jpn J Clin Oncol. 2010 Jan; 40(1):3-9. Epub 2009 Oct 19. 1969686
    View PubMed
  59. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol. 2009 Dec; 182(6):2708-14. 1975941
    View PubMed
  60. He M, Vanaja DK, Karnes RJ, Young CY. Epigenetic regulation of Myc on retinoic acid receptor beta and PDLIM4 in RWPE1 cells. Prostate. 2009 Nov 1; 69(15):1643-50. 1953751
    View PubMed
  61. McGee SM, Boorjian SA, Karnes RJ. Carcinosarcoma of the prostate replacing the entire lower genitourinary tract. Urology. 2009 Sep; 74(3):540-1. Epub 2009 Jul 08. 1952580
    View PubMed
  62. Gong A, He M, Krishna Vanaja D, Yin P, Karnes RJ, Young CY. Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells. Mol Nutr Food Res. 2009 Jul; 53(7):878-86. 2109201
    View PubMed
  63. Donovan MJ, Khan FM, Fernandez G, Mesa-Tejada R, Sapir M, Zubek VB, Powell D, Fogarasi S, Vengrenyuk Y, Teverovskiy M, Segal MR, Karnes RJ, Gaffey TA, Busch C, Haggman M, Hlavcak P, Freedland SJ, Vollmer RT, Albertsen P, Costa J, Cordon-Cardo C. Personalized prediction of tumor response and cancer progression on prostate needle biopsy. J Urol. 2009 Jul; 182(1):125-32. Epub 2009 May 17. 1962643
    View PubMed
  64. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009 Jun; 27(5):549-60. 2106808
    View PubMed
  65. Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 2009 Mar 15; 15(6):2174-80. Epub 2009 Mar 10. 1933613
    View PubMed
  66. Gettman MT, Pereira CW, Lipsky K, Wilson T, Arnold JJ, Leibovich BC, Karnes RJ, Dong Y. Use of high fidelity operating room simulation to assess and teach communication, teamwork and laparoscopic skills: initial experience. J Urol. 2009 Mar; 181(3):1289-96. Epub 2009 Jan 18. 1920608
    View PubMed
  67. Kipp BR, Tanasescu M, Else TA, Bryant SC, Karnes RJ, Sebo TJ, Halling KC. Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. J Mol Diagn. 2009 Mar; 11(2):148-54. Epub 2009 Jan 29. 1920507
    View PubMed
  68. Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, Eur Urol. 2009 Feb; 55(2):261-70. Epub 2008 Oct 1 2288575
    View PubMed
  69. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Sebo TJ, Blute ML. The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol. 2009 Jan; 181(1):95-104; discussion 104. Epub 2008 Nov 13. 1915368
    View PubMed
  70. Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, Karnes RJ, Leibovich BC. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer. 2008 Oct 1; 113(7):1544-51. 1904609
    View PubMed
  71. Kipp BR, Tyner HL, Campion MB, Voss JS, Karnes RJ, Sebo TJ, Halling KC, Zhang J. Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer. Am J Clin Pathol. 2008 Oct; 130(4):552-9. 1904617
    View PubMed
  72. Voss JS, Kipp BR, Krueger AK, Clayton AC, Halling KC, Karnes RJ, Henry MR, Sebo TJ. Changes in specimen preparation method may impact urine cytologic evaluation. Am J Clin Pathol. 2008 Sep; 130(3):428-33. 1898793
    View PubMed
  73. Miller J, Karnes RJ. Primary clear-cell adenocarcinoma of the proximal female urethra: case report and review of the literature. Clin Genitourin Cancer. 2008 Sep; 6(2):131-3. 1955037
    View PubMed
  74. Cheville JC, Karnes RJ, Therneau TM, Kosari F, Munz JM, Tillmans L, Basal E, Rangel LJ, Bergstralh E, Kovtun IV, Savci-Heijink CD, Klee EW, Vasmatzis G. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol. 2008 Aug 20; 26(24):3930-6. 1894810
    View PubMed
  75. Gettman MT, Karnes RJ, Arnold JJ, Klipfel JM, Vierstraete HT, Johnson ME, Johnson DR, Leibovich BC. Urology resident training with an unexpected patient death scenario: experiential learning with high fidelity simulation. J Urol. 2008 Jul; 180(1):283-8; discussion 288. Epub 2008 May 21. 1892698
    View PubMed
  76. Boorjian SA, Crispen PL, Carlson RE, Rangel LJ, Karnes RJ, Frank I, Gettman MT. Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic prostatectomy. J Endourol. 2008 Jul; 22(7):1471-6. 1904711
    View PubMed
  77. Karnes RJ, Blute ML. Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol. 2008 Jun; 5(6):329-39. Epub 2008 May 13. 1891614
    View PubMed
  78. Kipp BR, Halling KC, Campion MB, Wendel AJ, Karnes RJ, Zhang J, Sebo TJ. Assessing the value of reflex fluorescence in situ hybridization testing in the diagnosis of bladder cancer when routine urine cytological examination is equivocal. J Urol. 2008 Apr; 179(4):1296-301; discussion 1301. Epub 2008 Mar 04. 1902565
    View PubMed
  79. Thompson RH, Leibovich BC, Karnes RJ, Bergstralh EJ, Blute ML. Radical retropubic prostatectomy in immunosuppressed transplant recipients. J Urol. 2008 Apr; 179(4):1349-52; discussion 1352-3. Epub 2008 Mar 04. 1867610
    View PubMed
  80. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008 Apr; 179(4):1354-60; discussion 1360-1. Epub 2008 Mar 04. 1867611
    View PubMed
  81. Kosari F, Munz JM, Savci-Heijink CD, Spiro C, Klee EW, Kube DM, Tillmans L, Slezak J, Karnes RJ, Cheville JC, Vasmatzis G. Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res. 2008 Mar 15; 14(6):1734-43. 1879473
    View PubMed
  82. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int. 2008 Feb; 101(3):299-304. Epub 2007 Oct 08. 1861335
    View PubMed
  83. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. Epub 2007 Jul 16. 1841251
    View PubMed
  84. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007 Aug 15; 67(16):7893-900. Epub 2007 Aug 08. 1837117
    View PubMed
  85. Blute ML, Boorjian SA, Leibovich BC, Lohse CM, Frank I, Karnes RJ. Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. J Urol. 2007 Aug; 178(2):440-5; discussion 444. Epub 2007 Jun 11. 1834766
    View PubMed
  86. Miller J, Nwokeji C, Cunningham D, Karnes RJ:. Transitional Cell Carcinoma of the Renal Pelvis with Vena Caval Tumor Thrombus. Issues in Urology. October 2006; 18(5). 2288356
  87. Karnes RJ, Whelan CM, Kwon ED. Immunotherapy for prostate cancer. Curr Pharm Des. 2006; 12(7):807-17. 1752266
    View PubMed
  88. Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, Blute ML. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol. 2005 Jun; 173(6):1893-6. 1716434
    View PubMed
  89. Kramer SA, Rathbun SR, Elkins D, Karnes RJ, Husmann DA. Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population. J Urol. 2005 Jun; 173(6):2121-4; discussion 2124. 1714624
    View PubMed
  90. Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, Blute MM, Lieber MM, Zincke H, Halling KC. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol. 2005 Feb; 173(2):401-4. 1680861
    View PubMed
  91. Frank I, Cheville JC, Blute ML, Lohse CM, Karnes RJ, Weaver AL, Sebo TJ, Nehra A, Zincke H. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer. 2004 Oct 15; 101(8):1803-8. 1667524
    View PubMed
  92. Frank I, Cheville JC, Blute ML, Lohse CM, Nehra A, Weaver AL, Karnes RJ, Zincke H. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy - clinicopathologic features associated with outcome. Cancer. 2003 May 15; 97(10):2425-31. 1346769
    View PubMed
  93. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002 May; 167(5):2001-6. 1315477
    View PubMed
  94. Karnes RJ, Nehra A. Ventral, subcoronal, and penoscrotal penile approach for semirigid rod penile prostheses. Atlas of the urologic clinics of North America. 2002; 10(2):181-8. 1652503
    View PubMed
  95. Karnes RJ, Gettman MT, Anderson PM, Lager DJ, Blute ML. Primitive neuroectodermal tumor (extraskeletal Ewing's sarcoma) of the kidney with vena caval tumor thrombus. J Urol. 2000 Sep; 164(3 Pt 1):772. 1012539
    View PubMed